SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kraig Biocraft Laboratories, Inc. – ‘S-1/A’ on 5/25/22 – ‘EX-23.1’

On:  Wednesday, 5/25/22, at 4:55pm ET   ·   Accession #:  1493152-22-15052   ·   File #:  333-238883

Previous ‘S-1’:  ‘S-1/A’ on 4/14/22   ·   Next:  ‘S-1/A’ on 12/1/22   ·   Latest:  ‘S-1/A’ on 11/22/23   ·   18 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/25/22  Kraig Biocraft Laboratories, Inc. S-1/A                 64:12M                                    M2 Compliance LLC/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Pre-Effective Amendment to Registration Statement   HTML   2.92M 
                (General Form)                                                   
 2: EX-23.1     Consent of Expert or Counsel                        HTML     19K 
 8: R1          Cover                                               HTML     52K 
 9: R2          Condensed Consolidated Balance Sheets               HTML    126K 
10: R3          Condensed Consolidated Balance Sheets               HTML     49K 
                (Parenthetical)                                                  
11: R4          Condensed Consolidated Statements of Operations     HTML     88K 
12: R5          Condensed Consolidated Statement of Changes in      HTML     86K 
                Stockholders Deficit                                             
13: R6          Condensed Consolidated Statement of Changes in      HTML     30K 
                Stockholders Deficit (Parenthetical)                             
14: R7          Consolidated Statements of Cash Flows               HTML    128K 
15: R8          Summary of Significant Accounting Policies and      HTML    204K 
                Organization                                                     
16: R9          Going Concern                                       HTML     27K 
17: R10         Equipment                                           HTML     47K 
18: R11         Right to Use Assets and Lease Liabilitity           HTML     73K 
19: R12         Accrued Interest - Related Party                    HTML     45K 
20: R13         Note Payable                                        HTML     44K 
21: R14         Convertible Notes                                   HTML    189K 
22: R15         Stockholders? Deficit                               HTML    524K 
23: R16         Commitments and Contingencies                       HTML    130K 
24: R17         Related Party Transactions                          HTML    111K 
25: R18         Subsequent Events                                   HTML     32K 
26: R19         Summary of Significant Accounting Policies and      HTML    241K 
                Organization (Policies)                                          
27: R20         Summary of Significant Accounting Policies and      HTML    125K 
                Organization (Tables)                                            
28: R21         Equipment (Tables)                                  HTML     42K 
29: R22         Right to Use Assets and Lease Liabilitity (Tables)  HTML     51K 
30: R23         Convertible Notes (Tables)                          HTML    103K 
31: R24         Stockholders? Deficit (Tables)                      HTML    354K 
32: R25         Schedule of Antidilutive Securities of Earnings     HTML     41K 
                Per Share (Details)                                              
33: R26         Schedule of Antidilutive Securities of Earnings     HTML     25K 
                Per Share (Details) (Parenthetical)                              
34: R27         Schedule of Fair Value of Financial Instruments     HTML     28K 
                (Details)                                                        
35: R28         Schedule of Gold in Bullion (Details)               HTML     39K 
36: R29         Summary of Significant Accounting Policies and      HTML     37K 
                Organization (Details Narrative)                                 
37: R30         Going Concern (Details Narrative)                   HTML     28K 
38: R31         Schedule of Property and Equipment (Details)        HTML     36K 
39: R32         Equipment (Details Narrative)                       HTML     24K 
40: R33         Schedule of Right Use of Assets (Details)           HTML     26K 
41: R34         Schedule of Lease Liability (Details)               HTML     30K 
42: R35         Schedule of Lease Cost (Details)                    HTML     28K 
43: R36         Right to Use Assets and Lease Liabilitity (Details  HTML     69K 
                Narrative)                                                       
44: R37         Accrued Interest - Related Party (Details           HTML     48K 
                Narrative)                                                       
45: R38         Note Payable (Details Narrative)                    HTML     71K 
46: R39         Schedule of Fair Value Warrants (Details)           HTML     39K 
47: R40         Summary of Convertible Debt (Details)               HTML     51K 
48: R41         Convertible Notes (Details Narrative)               HTML    182K 
49: R42         Schedule of Option Assumption (Details)             HTML     99K 
50: R43         Schedule of Warrants Activity (Details)             HTML     45K 
51: R44         Schedule of Warrants Outstanding (Details)          HTML     63K 
52: R45         Schedule of Options Outstanding (Details)           HTML     28K 
53: R46         Stockholders? Deficit (Details Narrative)           HTML    452K 
54: R47         Commitments and Contingencies (Details Narrative)   HTML    433K 
55: R48         Related Party Transactions (Details Narrative)      HTML    365K 
56: R49         Schedule of Deferred Tax Assets and Liabilities     HTML     32K 
                (Details)                                                        
57: R50         Schedule of Deferred Tax Assets and Liabilities     HTML     21K 
                (Details) (Parenthetical)                                        
58: R51         Schedule of Components Deferred Income Taxes        HTML     30K 
                (Details)                                                        
59: R52         Subsequent Events (Details Narrative)               HTML     34K 
62: XML         IDEA XML File -- Filing Summary                      XML    115K 
60: XML         XBRL Instance -- forms-1a_htm                        XML   3.55M 
61: EXCEL       IDEA Workbook of Financial Reports                  XLSX    105K 
 4: EX-101.CAL  Inline XBRL Taxonomy Extension Calculation           XML    139K 
                Linkbase Document -- kblb-20211231_cal                           
 5: EX-101.DEF  Inline XBRL Taxonomy Extension Definition Linkbase   XML    766K 
                Document -- kblb-20211231_def                                    
 6: EX-101.LAB  Inline XBRL Taxonomy Extension Label Linkbase        XML   1.13M 
                Document -- kblb-20211231_lab                                    
 7: EX-101.PRE  Inline XBRL Taxonomy Extension Presentation          XML    926K 
                Linkbase Document -- kblb-20211231_pre                           
 3: EX-101.SCH  Inline XBRL Taxonomy Extension Schema Document --    XSD    180K 
                kblb-20211231                                                    
63: JSON        XBRL Instance as JSON Data -- MetaLinks              351±   468K 
64: ZIP         XBRL Zipped Folder -- 0001493152-22-015052-xbrl      Zip    420K 


‘EX-23.1’   —   Consent of Expert or Counsel


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 15, 2022 relating to the consolidated financial statements which appeared in Kraig Biocraft Laboratories, Inc.’s Annual Report on Form 10-K for the years ended December 31, 2021.

 

/s/ M&K CPAs, PLLC

 
www.mkacpas.com  
Houston, Texas  
   
May 25, 2022  

 

 C: 
 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-1/A’ Filing    Date    Other Filings
Filed on:5/25/224
3/15/22
12/31/2110-K
 List all Filings 


18 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/14/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:10M                                    M2 Compliance LLC/FA
 1/20/22  Kraig Biocraft Laboratories, Inc. 8-K:1,2,8,9 1/20/22   18:1.4M                                   M2 Compliance LLC/FA
 3/26/21  Kraig Biocraft Laboratories, Inc. 8-K:1,2,8,9 3/26/21   10:1.2M                                   M2 Compliance LLC/FA
 1/26/21  Kraig Biocraft Laboratories, Inc. 8-K:1,3,8,9 1/26/21    4:217K                                   M2 Compliance LLC/FA
12/11/20  Kraig Biocraft Laboratories, Inc. 8-K:1,2,8,912/11/20    5:541K                                   M2 Compliance LLC/FA
 6/02/20  Kraig Biocraft Laboratories, Inc. S-1                   71:7.9M                                   M2 Compliance LLC/FA
 3/27/20  Kraig Biocraft Laboratories, Inc. 10-K       12/31/19   62:4.6M                                   M2 Compliance LLC/FA
 3/31/15  Kraig Biocraft Laboratories, Inc. 10-K       12/31/14   50:4.1M                                   Issuer Direct/FA
 1/30/15  Kraig Biocraft Laboratories, Inc. S-1/A                  6:5.4M                                   Issuer Direct/FA
 1/21/15  Kraig Biocraft Laboratories, Inc. 8-K:5,7,9   1/20/15    3:98K                                    Issuer Direct/FA
12/19/13  Kraig Biocraft Laboratories, Inc. 8-K:3,5,9  12/17/13    2:901K                                   Issuer Direct/FA
11/22/13  Kraig Biocraft Laboratories, Inc. 8-K:5,9    11/15/13    2:678K                                   Issuer Direct/FA
 8/01/11  Kraig Biocraft Laboratories, Inc. S-1                    4:3.4M                                   EdgarAgents LLC/FA
 4/15/10  Kraig Biocraft Laboratories, Inc. 10-K       12/31/09    5:1.5M                                   EdgarAgents LLC/FA
 1/25/10  Kraig Biocraft Laboratories, Inc. S-1/A                  3:2.5M                                   EdgarAgents LLC/FA
10/02/09  Kraig Biocraft Laboratories, Inc. S-1                    4:2.3M                                   EdgarAgents LLC/FA
 3/26/08  Kraig Biocraft Laboratories, Inc. 10KSB      12/31/07    4:881K                                   EdgarAgents LLC/FA
 9/26/07  Kraig Biocraft Laboratories, Inc. SB-2                   9:1.7M                                   EdgarAgents LLC/FA
Top
Filing Submission 0001493152-22-015052   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 8:49:55.2pm ET